Lyell Immunopharma, Inc. (LYEL)
NASDAQ:LYEL
Want to see LYEL full AI Analyst Report?
Total Valuation
Lyell Immunopharma has a market cap or net worth of $401.81M. The enterprise value is $350.53M.
Market Cap$401.81M
Enterprise Value$350.53M
Share Statistics
Lyell Immunopharma has 23,334,087 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,334,087
Owned by Insiders28.57%
Owned by Institutions36.69%
Financial Efficiency
Lyell Immunopharma’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -70.11%.
Return on Equity (ROE)-1.11
Return on Assets (ROA)-0.81
Return on Invested Capital (ROIC)-70.11%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee120.00
Profits Per Employee-914.83K
Employee Count300
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyell Immunopharma is ―. Lyell Immunopharma’s PEG ratio is -0.00170.
PE Ratio―
PS Ratio14614.51
PB Ratio2.12
Price to Fair Value2.12
Price to FCF-3.49
Price to Operating Cash Flow-2.82
PEG Ratio-0.00170
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 36.00K and earned -274.45M in profits. Earnings per share was -16.06.
Revenue36.00K
Gross Profit-11.50M
Operating Income-203.77M
Pretax Income-274.45M
Net Income-274.45M
EBITDA-192.24M
Earnings Per Share (EPS)-16.06
Cash Flow
In the last 12 months, operating cash flow was -133.80M and capital expenditures -623.00K, giving a free cash flow of -134.42M billion.
Operating Cash Flow-133.80M
Free Cash Flow-134.42M
Free Cash Flow per Share-5.76
Dividends & Yields
Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change110.00%
50-Day Moving Average21.13
200-Day Moving Average20.42
Relative Strength Index (RSI)34.29
Average Volume (3m)78.15K
Important Dates
Lyell Immunopharma upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Lyell Immunopharma as a current ratio of 5.28, with Debt / Equity ratio of 14.43%
Current Ratio5.28
Quick Ratio5.28
Debt to Market Cap0.00
Net Debt to EBITDA0.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyell Immunopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lyell Immunopharma EV to EBITDA ratio is -2.64, with an EV/FCF ratio of -3.37.
EV to Sales14.11K
EV to EBITDA-2.64
EV to Free Cash Flow-3.37
EV to Operating Cash Flow-3.39
Balance Sheet
Lyell Immunopharma has $254.02M in cash and marketable securities with $39.49M in debt, giving a net cash position of $214.54M billion.
Cash & Marketable Securities$254.02M
Total Debt$39.49M
Net Cash$214.54M
Net Cash Per Share$9.19
Tangible Book Value Per Share$14.52
Margins
Gross margin is -7422.58%, with operating margin of -566038.89%, and net profit margin of -762355.56%.
Gross Margin-7422.58%
Operating Margin-566038.89%
Pretax Margin-762355.56%
Net Profit Margin-762355.56%
EBITDA Margin-533986.11%
EBIT Margin-566038.89%
Analyst Forecast
The average price target for Lyell Immunopharma is $36.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$36.80
Price Target Upside53.27% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast-52.31%
EPS Growth Forecast49.06%